piperlongumine hydrogel (TTX101) / TargTex - LARVOL DELTA

Nanoformed TargTex oncology drug candidate TTX101 receives FDA Orphan Drug Designation (Cision) - "Nanoform Finland Plc...announced its customer TargTex S.A. has been granted Orphan Drug Designation by the FDA for its nanoformed drug candidate TTX101 to be used in patients with malignant gliomas. The orphan drug designation follows the generation of a preclinical rodent data package in which a survival advantage was shown for this nanoform-enabled medicine candidate....TargTex is currently raising funds to take this innovative treatment to clinic and is planning a phase 1/2a clinical trial in recurrent glioblastoma (GBM) patients across the US and EU, in which nanoformed TTX101 is applied as adjunct to surgery after tumour excision."

Financing • Orphan drug • Glioblastoma

Orphan Designation: Treatment of malignant glioma (FDA) - Date Designated: 09/19/2023

Orphan drug • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor